Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Purpose Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib’s effectiveness and safety in AD adolescents in daily practice.Materials and methods Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15...

Full description

Saved in:
Bibliographic Details
Main Authors: Florence Vroman, Lisa P. van der Rijst, Octavian I. Bacoş-Cosma, Nicolaas P. A. Zuithoff, Marijke Kamsteeg, Paula P. M. van Lumig, Laura Loman, Marie-Louise L. A. Schuttelaar, Marjolein S. de Bruin-Weller, Marlies de Graaf
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Atopic dermatitis
upadacitinib
adolescents
effectiveness
daily practice
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2025.2539282
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2025.2539282

Similar Items